ABCLONAL TECHNOLOGY
LIVE

Serial Number

86837812

Owner

Wuhan ABclonal Biotechnology Co., Ltd

Attorney

Kevin L. Russell

First Use Date

Aug 26, 2013

Filing Date

Dec 3, 2015

Add to watchlist:

No watchlists yet
View on USPTO

ABCLONAL TECHNOLOGY Trademark

Serial Number: 86837812 • Registration: 5030497

ABCLONAL TECHNOLOGY is a trademark filed by Wuhan ABclonal Biotechnology Co., Ltd on December 3, 2015. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Wuhan ABclonal Biotechnology Co., Ltd

Fl.4, Bldg. 7, 388 Gaoxin Er Rd.
Wuhan 430233 , CN

Entity Type: 03

Trademark Details

Filing Date

December 3, 2015

Registration Date

August 30, 2016

First Use Anywhere

August 26, 2013

First Use in Commerce

August 26, 2013

Published for Opposition

June 14, 2016

Goods & Services

Diagnostic kits consisting of monoclonal antibodies, buffers, reagents for use in disease testing; Diagnostic kits consisting of recombinant proteins, buffers, reagents for use in disease testing

Biochemicals, namely, polyclonal antibodies for in vitro scientific or research use; diagnostic kits consisting of polyclonal antibodies, buffers, and reagents for scientific and research use; biochemicals, namely, polyclonal antibodies for the detection of antigens; diagnostic kits consisting of polyclonal antibodies, buffers, reagents for use in disease testing; biochemicals, namely, custom polyclonal antibodies specifically recognizing antigens provided by customer; biochemicals, namely, monoclonal antibodies for in vitro scientific or research use; diagnostic kits consisting of monoclonal antibodies, buffers, and reagents for scientific and research use; biochemicals, namely, monoclonal antibodies for the detection of antigens; biochemicals, namely, custom monoclonal antibodies specifically recognizing antigens provided by customer; Enzyme-linked immunosorbent assay kits comprised of assays and reagents for scientific and research use; chemical reagents, namely, recombinant protein for scientific and research use; chemicals, namely, custom recombinant proteins manufactured for others; biochemical kits consisting of recombinant proteins, buffers, reagents for scientific and research use

custom design and development of polyclonal antibodies specifically recognizing an antigen; custom design and development of kits consisting polyclonal antibodies specifically recognizing an antigen, buffers, reagents for scientific and research use; custom design and development of kits consisting of polyclonal antibodies specifically recognizing an antigen, buffers, reagents for detection of the antigen; custom design and development of monoclonal antibodies specifically recognizing an antigen; custom design and development of kits consisting of monoclonal antibodies specifically recognizing an antigen, buffers, reagents for scientific and research use; custom design and development of kits consisting of monoclonal antibodies specifically recognizing an antigen, buffers, reagents for detection of the antigen; custom design and development of recombinant proteins for others; Custom design and development of enzyme-linked immunosorbent assay kits consisting of polyclonal antibodies recognizing an antigen, buffers, reagents; Custom design and development of enzyme-linked immunosorbent assay kits consisting of monoclonal antibodies recognizing an antigen, buffers, reagents; Custom design and development of recombinant proteins for scientific and research use; Custom design and development of kits consisting of recombinant proteins, buffers, reagents for scientific and research use; Custom design and development of diagnostic kits consisting of recombinant proteins, buffers, reagents for use in disease testing

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 14, 2026 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 14, 2026 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 14, 2026 REAP
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Jan 30, 2026 NA89
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Jan 30, 2026 RNL1
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Jan 30, 2026 89AG
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jan 30, 2026 APRE
TEAS SECTION 8 & 9 RECEIVED
Oct 27, 2025 E89R
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Aug 30, 2025 REM2
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Jan 31, 2022 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Jan 31, 2022 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Dec 14, 2021 APRE
TEAS SECTION 8 & 15 RECEIVED
Sep 13, 2021 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Aug 30, 2021 REM1
REGISTERED-PRINCIPAL REGISTER
Aug 30, 2016 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 14, 2016 NPUB
PUBLISHED FOR OPPOSITION
Jun 14, 2016 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 25, 2016 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 6, 2016 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 4, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 3, 2016 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 3, 2016 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 5, 2016 GNRN
NON-FINAL ACTION E-MAILED
Apr 5, 2016 GNRT
NON-FINAL ACTION WRITTEN
Apr 5, 2016 CNRT
ASSIGNED TO EXAMINER
Mar 22, 2016 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Dec 9, 2015 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 8, 2015 NWOS
NEW APPLICATION ENTERED
Dec 7, 2015 NWAP